Foster City, CA, United States of America

Rao S S Kolluri

This inventor holds 1 USPTO granted patent. Top assignee: Rigel Pharmaceuticals, Incorporated. Active years: 2009.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Rao S S Kolluri. Retrieved from https://idiyas.com/inventor/rao-s-s-kolluri

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2009

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Rao S S Kolluri

Introduction

Rao S S Kolluri, based in Foster City, California, is a notable inventor recognized for his groundbreaking work in the field of antiviral compounds. With one patent to his name, Kolluri's contributions represent a significant advancement in the treatment of viral infections, particularly focusing on Hepatitis C virus (HCV).

Latest Patents

Kolluri's patent, titled "Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses," pertains to prodrugs and compositions designed for treating or preventing HCV infections. This invention specifically addresses the development of prodrugs made from substituted diphenyl-, diheteroaryl-, and mixed phenyl heteroaryl substituted five-membered heterocycle compounds. These compounds and their associated compositions offer promising therapeutic approaches to inhibit HCV replication in both humans and animals.

Career Highlights

Rao S S Kolluri currently works at Rigel Pharmaceuticals, Incorporated, where he applies his expertise to innovate therapeutic solutions for challenging health issues. His career has been marked by a focus on antiviral research, contributing to the understanding and treatment of viral diseases.

Collaborations

Throughout his career, Kolluri has collaborated with several esteemed colleagues, including Rajinder Paul Singh and Dane A Goff. This team of innovators has fostered an environment of shared ideas and expertise, enriching the development of effective antiviral therapies.

Conclusion

Rao S S Kolluri stands out as an inventor in the biopharmaceutical landscape, contributing significantly to the treatment of HCV infections. His patent for heterocyclic anti-viral compounds showcases his commitment to advancing medical science and improving patient outcomes. With continuing efforts and innovative partnerships, Kolluri's work promises to make lasting impacts on the field of antiviral therapy.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…